About Us / Blogs

Gene Editing Services

Ubigene has modified over 5000 genes from more than 100 cell lines with our exclusive innovation CRISPR-U™ technology. At the same time, we already provide customers with high quality gene-editing tools for cell or animal research worldwide.

Stable Cell Lines

Knockout Cell Lines

Knockdown Cell Lines

Overexpression Cell Lines

Knockin Cell Lines

Point Mutation Cell Line

Cloning Services

Knockout Plasmid

Point Mutation Plasmid

Knockin Plasmid

Overexpression Plasmid

Knockdown Plasmid

Virus Packaging

Lentivirus Packaging

Adenovirus Packaging

Adeno-associated Virus Packaging

Microbe

Knockout E.coli

Knockout Salmonella

Cell Assay

Cell Proliferation

Cell Migration and Invasion

Cell Cycle

Cell Apoptosis

Detection of Marker Protein Expression

Cytokine Secretion and Enzyme Activity Test

Cytotoxicity Test

EZ-editor™
Gene-editing Series Products

With 12 years of experience, Ubigene has exclusively innovated and developed 6 product lines, fullfilling all kinds of needs from researchers. Experiment process simplified, efficiency improved, achieving our aim of 'Make genome editing easier'!

Red Cotton™ gRNA Plasmid Bank

Regular Plasmid

Lentiviral Plasmid

EZ-editor™ Culture Medium

Transfection Culture Medium

Cell Monoclonal Culture Medium

Knockout-cell-lysate

KO cell lysates (clone)

KO cell lysates (pool)

EZ-editor™ Cell Line

KO Cell Lines

Wild-type Cell Lines

Cas9 Stable Cell Lines

Luciferase Stable Cell Lines

EGFP Stable Cell Lines

EZ-editor™ Kits

Monoclone Validation Kit (extraction free)

EZ-editor™ Gene Knockout kit

Lentiviral Packaging Kit

Mycoplasma Treatment kit

Lentivirus

Red Cotton Gene knockout Project

Ubigene exclusive KO Cell Line Bank, over 5000 KO cell lines, covering thousands of genes from 8 popular signaling pathways and nearly 100 diseases.

Red Cotton CRISPR Gene Editing Designer

Gene Editing Cell Designer

Gene Editing Microbe Designer

Gene Editing Tool Kit

Red Cotton Gene knockout Project

Location：Home > About Us > Blogs >

Contact us✖

* Name：

* E-mail：

*Phone：

Institution：

* Project Description：

Source：

Other

New “Prime Editing” Method Makes Only Single-Stranded DNA Cuts

In demonstrations in cell lines, the technique has a similar efficacy to CRISPR-Cas9, but fewer off-target effects.
2020-06-02
Early Results Are Positive for Experimental CRISPR Therapies

Two clinical trial participants—one with β-thalassemia and one with sickle cell disease—appeared to benefit from the gene-editing treatments with minimal side effects, according to the companies.
2020-06-01
CRISPR Can Create Unwanted Duplications During Knock-ins

In less than a decade since its adaptation to a genome-editing technique, CRISPR-Cas9 has been used on lab animals and cells around the world, as well on human cells that are already being tested in clinical trials to treat disease. Limitations such as off-target edits are widely …
2020-05-29
Gene editing can knock out genes crucial to cervical tumor cells’ survival, researchers report.

When the human papillomavirus enters a cervix, it doesn’t lyse cells or cause inflammation. While some strains can cause genital warts, in most cases the body clears the virus without much fuss. But “in an unfortunate number of people, the virus gets stuck,” says Nigel McMil…
2020-05-28
CRISPR-Based In Vivo Genome Editing and Base Editing

CRISPR genome editing tools are driving innovations in precision genetic medicine. However, in vivo delivery of CRISPR components for treating diseases remains a challenge as researchers strive to eliminate or reduce off-target effects, provide transient editing systems, and incre…
2020-05-27
Symptoms in ALS Mouse Model Improve with CRISPR Base Editing

Researchers slowed disease progression in the mice by injecting two different viral vectors, each containing one part of the DNA encoding the Cas9 protein, to edit the causative gene.
2020-05-25
A New Lease on Life for shRNA

Horizon Discovery describes how short hairpin RNA is advancing the development of chimeric antigen receptor T-cell therapies
2020-05-22
COVID-19 Drives CRISPR Diagnostics

Mammoth Biosciences is responding to the urgent need for improved and more accessible testing for COVID-19 by rapidly reconfiguring the company’s CRISPR-based diagnostics platform to detect the presence of SARS-CoV-2. In April, the company published a study demonstrating the pow…
2020-05-21
MilliporeSigma Awarded 2 U.S. Patents toward CRISPR-Cas9-Assisted Genome Editing

MilliporeSigma said it has been granted two U.S. patents toward CRISPR-Cas9-assisted genome-editing, the company's 25th and 26th CRISPR patents worldwide and third and fourth in the U.S. [Janet Iwasa for the Innovative Genomics Institute at UC Berkeley]
2020-05-20